|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Boston Scientific (NYSE: BSX), a manufacturer of less-invasive medical devices. |
|---|---|
| Transferring Party | Guidant (NYSE: GDT), a manufacturer of cardiovascular medical devices. |
| Sector | Medical Devices |
| Date | April 21, 2006 |
| Analysis Outbidding J&J, BSX fortifies itself as a global leader in cardiovascular devices. Boston Scientific has also completed an agreement with Abbott acquiring Guidant’s vascular intervention and endovascular businesses, while agreeing to share rights to Guidant’s drug-eluting stent program with Boston Scientific. Deal Value - $27b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |